AVADEL PHARMACEUTICALS PLC

(AVDL)
  Report
Delayed Nasdaq  -  05/13 04:00:00 pm EDT
3.800 USD   +7.19%
05/13European ADRs Move Higher in Friday Trading
MT
05/10European ADRs Move Higher in Tuesday Trading
MT
05/10Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/09/2022 05/10/2022 05/11/2022 05/12/2022 05/13/2022 Date
3.93(c) 3.97(c) 3.68(c) 3.545(c) 3.8(c) Last
683 558 635 786 393 430 601 042 460 791 Volume
-5.98% +1.02% -7.30% -3.67% +7.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 18,4 M - -
Net income 2022 -108 M - -
Net Debt 2022 123 M - -
P/E ratio 2022 -2,27x
Yield 2022 -
Sales 2023 140 M - -
Net income 2023 2,79 M - -
Net Debt 2023 165 M - -
P/E ratio 2023 28,9x
Yield 2023 -
Capitalization 224 M 224 M -
EV / Sales 2022 18,9x
EV / Sales 2023 2,78x
Nbr of Employees 66
Free-Float 60,4%
More Financials
Company
Avadel Pharmaceuticals plc is a biopharmaceutical company. The CompanyÔÇÖs lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Ratings of Avadel Pharmaceuticals plc
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about AVADEL PHARMACEUTICALS PLC
05/13European ADRs Move Higher in Friday Trading
MT
05/10European ADRs Move Higher in Tuesday Trading
MT
05/10Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financi..
AQ
05/09AVADEL PHARMACEUTICALS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
05/09TRANSCRIPT : Avadel Pharmaceuticals plc, Q1 2022 Earnings Call, May 09, 2022
CI
05/09AVADEL : Q1 Earnings Snapshot
AQ
05/09AVADEL PHARMACEUTICALS PLC : Results of Operations and Financial Condition (form 8-K)
AQ
05/09Avadel Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 3..
CI
05/09Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financi..
AQ
05/03European ADRs Climb Higher in Tuesday Trading
MT
05/02European ADRs Move Slightly Lower in Monday Trading
MT
05/02Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial..
AQ
04/29European ADRs Nudge Higher in Friday Trading
MT
04/28European ADRs Nudge Lower in Thursday Trading
MT
04/27European ADRs Nudge Higher in Wednesday Trading
MT
More news
News in other languages on AVADEL PHARMACEUTICALS PLC
05/13Les ADR européens sont en hausse vendredi
05/10Les ADR européens sont en hausse mardi
05/09Avadel Pharmaceuticals plc annonce ses résultats pour le premier trimestre clos le 31 m..
05/03Les ADR européens grimpent dans les échanges de mardi
05/02Les ADR européens sont en légère baisse dans les échanges de lundi
More news
Analyst Recommendations on AVADEL PHARMACEUTICALS PLC
More recommendations
Chart AVADEL PHARMACEUTICALS PLC
Duration : Period :
Avadel Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVADEL PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 3,80 $
Average target price 16,30 $
Spread / Average Target 329%
EPS Revisions
Managers and Directors
Gregory J. Divis Chief Executive Officer & Director
Thomas S. McHugh Chief Financial Officer & Senior Vice President
Geoffrey Michael Glass Non-Executive Chairman
Jason Vaughn Senior Vice President-Technical Operations
Jennifer Gudeman Vice President-Medical & Clinical Affairs
Sector and Competitors
1st jan.Capi. (M$)
AVADEL PHARMACEUTICALS PLC-52.97%224
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421